NCT00280098View on ClinicalTrials.gov

Docetaxel in the Treatment of Hormone Refractory Prostate Cancer

PHASE4CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

October 31, 2007

Conditions

Prostatic Neoplasms

Interventions

DRUG

docetaxel

Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid

Trial Locations (1)

Unknown

Sanofi-Aventis, Prague

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY